Analyst Josh Jennings of TD Cowen maintained a Buy rating on Anteris Technologies Global Corp. (AVR – Research Report), retaining the price target of $15.00.
Josh Jennings has given his Buy rating due to a combination of factors, primarily focusing on Anteris Technologies Global Corp.’s significant advancements toward FDA approval for their DurAVR TAVR system. The company has made notable strides in preparing for the pivotal trial, which is crucial for gaining regulatory approval.
Key activities such as engaging in pre-submission meetings with the FDA, finalizing trial designs, and expanding clinical experience demonstrate Anteris’s commitment to moving forward. Additionally, the successful completion of essential validation steps, including life cycle testing and human factors validation, further supports the company’s progress. These developments collectively indicate a positive trajectory for Anteris, justifying the Buy rating.